Immutep Limited (IMMP), an Australian biotech company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces it participated in two post presentations at ASCO Chicago. TACT-001 (Two ACTive Immunotherapies) A Phase II clinical trial...